NMN and NR Real-World Evidence: What Women Actually Need to Know

What NMN and NR Actually Do in the Body

NMN and NR are two upstream precursors that the body converts to NAD+ (nicotinamide adenine dinucleotide), a coenzyme found in every cell and required for energy metabolism, DNA repair, and sirtuin activity. When you take either compound orally, the liver and intestinal cells do most of the conversion work, though the exact intracellular routing differs between the two molecules.

NAD+ declines with age. Blood NAD+ levels in middle-aged and older adults are roughly 50 percent lower than in young adults, a drop that coincides with worsening mitochondrial efficiency, increased oxidative stress, and the metabolic shifts seen across perimenopause and postmenopause. Whether topping up NAD+ through supplementation reverses any of those changes in women is the central clinical question.

The Conversion Pathway: NMN vs. NR

NR is phosphorylated intracellularly to NMN, which is then converted to NAD+. NMN can also be dephosphorylated to NR before crossing the cell membrane, then re-phosphorylated inside. Both pathways converge at NAD+, but their kinetics and tissue distribution may differ. A 2023 pharmacokinetic study in healthy adults found that a single oral dose of 1,000 mg NMN raised whole-blood NAD+ by approximately 2.5-fold over baseline within 4 hours, though that study included more men than women and did not stratify by sex.

Sirtuin Activation and DNA Repair

NAD+ is the obligate substrate for sirtuins (SIRT1 through SIRT7) and PARPs, enzymes central to DNA repair and cellular stress response. SIRT1 activity in adipose tissue correlates inversely with insulin resistance, which is relevant for women with PCOS and for postmenopausal women whose insulin sensitivity drops after estrogen loss. This mechanism is plausible, but showing that oral NMN raises tissue NAD+ enough to meaningfully activate sirtuins in humans, not just in mice, requires specific human tissue biopsy data that only one published trial has attempted.

Why Women's Physiology Changes the Picture

Estrogen regulates the NAMPT enzyme, the rate-limiting step in the salvage pathway that recycles NAD+. NAMPT expression in adipose tissue declines significantly after menopause, which may explain why postmenopausal women show more pronounced NAD+ depletion than age-matched men. This is not a minor footnote. It means the mechanistic case for NAD+ precursor supplementation may actually be stronger in postmenopausal women than in the male-predominant populations studied in most longevity trials.

The Yoshino 2021 Trial: The Only Placebo-Controlled RCT in Women

This is the most important piece of evidence for women considering NMN, and it deserves a careful read rather than a headline summary.

Yoshino et al. Published in Science in May 2021 enrolled 25 postmenopausal women with prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4 percent) in a randomized, double-blind, placebo-controlled crossover trial. Participants received 250 mg/day oral NMN or placebo for 10 weeks, then crossed over after a washout.

What Changed and What Did Not

NMN increased skeletal-muscle NAD+ metabolites, confirmed by muscle biopsy. The primary outcome, insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, improved significantly in the NMN group (mean improvement approximately 25 percent over placebo, p = 0.026). Skeletal-muscle insulin signaling genes, including INSR and PIK3CA, were upregulated on RNA sequencing, suggesting a real molecular effect rather than measurement noise.

What did not change: body weight, fat mass, lean mass, fasting glucose, fasting insulin, HbA1c, blood pressure, or lipids. None of these secondary outcomes reached statistical significance.

What This Means for You

The trial tells you that NMN at 250 mg/day can improve how muscle uses insulin in postmenopausal women with early metabolic dysfunction, and that this effect appears to be mediated through muscle NAD+ repletion, not through weight loss or changes in body composition. The sample size was 25 women. That is enough to generate a hypothesis and justify further study. It is not enough to guide population-level recommendations.

A clinical decision framework for postmenopausal women: if your primary concern is insulin resistance not yet meeting the threshold for pharmacologic intervention, and you have already optimized lifestyle, NMN at 250 mg/day represents a low-harm adjunct with one RCT showing mechanistic plausibility. Do not use it as a substitute for metformin or GLP-1 therapy if those are indicated.

What Real-World Evidence Actually Exists

"Real-world evidence" in the regulatory sense means data collected outside a controlled trial: insurance claims, electronic health record databases, patient registries, pharmacovigilance reports, or prospective cohorts. For NMN and NR, this infrastructure barely exists.

Why RWE Is Sparse

Because NMN and NR are sold as dietary supplements in the United States, manufacturers are not required to report adverse events to the FDA through MedWatch unless they become aware of a serious adverse event. The FDA's dietary supplement adverse event reporting system (CFSAN Adverse Event Reporting System, CAERS) contains far fewer entries per user than the equivalent pharmaceutical database, which systematically undercounts both harms and benefits.

No NMN- or NR-specific patient registry exists as of mid-2025. The National Institutes of Health's ClinicalTrials.gov lists over 30 registered trials involving NMN or NR, but most are small, short-duration, and few are powered to detect outcomes in women specifically.

Published Human Trials Beyond Yoshino 2021

A 2023 randomized trial by Yi et al. In healthy middle-aged adults (mixed sex, n = 80) tested 300 mg/day and 600 mg/day NMN for 60 days. Both doses raised blood NAD+ without significant adverse events, but metabolic outcomes were not primary endpoints and sex-stratified data were not reported separately. This is the evidence-gap problem in practice: even when women are enrolled, the data are not analyzed by sex.

A 2021 NR trial by Dollerup et al. In obese men did not enroll women at all. A 2022 multi-dose NR trial (Martens et al., published in Nature Communications) enrolled both sexes and showed dose-dependent blood NAD+ increases at 1,000 mg/day, but sex-specific metabolic outcomes were not reported.

The Honest Verdict on RWE

There is no NMN or NR registry. There are no large observational datasets. There is one rigorous RCT in postmenopausal women (n = 25) and a handful of mixed-sex pharmacokinetic studies. Anyone claiming to cite "real-world evidence" for NMN in women is either describing survey data from supplement company databases or extrapolating from the broader NAD+ biology literature. Both can be informative, but neither meets the standard definition of RWE.

NMN, NR, and Women-Specific Conditions

PCOS and Insulin Resistance

Women with PCOS carry a disproportionate burden of insulin resistance, with approximately 70 percent of women with PCOS showing some degree of insulin dysregulation regardless of body weight. Mitochondrial dysfunction is increasingly recognized as a driver of PCOS pathophysiology, and NAD+ depletion has been documented in ovarian granulosa cells in animal models of PCOS. No published human RCT has tested NMN or NR specifically in women with PCOS. The mechanistic rationale is plausible. The clinical evidence is absent.

Perimenopause and Menopause

The hormonal shift of perimenopause accelerates the age-related decline in NAMPT activity and NAD+ availability. Estrogen directly upregulates NAMPT transcription through estrogen response elements in the gene promoter, so the loss of estrogen after menopause creates a double hit: less NAD+ production and more oxidative stress from metabolic change. The Yoshino trial targeted exactly this population, which is why it remains the anchor evidence for clinical discussion.

Women in perimenopause, those with irregular cycles but not yet 12 months without a period, have not been studied in any NMN trial. Whether the partially preserved estrogen milieu of perimenopause attenuates the benefit seen in postmenopausal women is unknown.

Female Pattern Hair Loss and Skin Aging

NAD+ participates in PARP-mediated DNA repair in dermal fibroblasts and follicle stem cells. Small, industry-sponsored surveys have reported subjective improvements in hair thickness and skin elasticity with NR supplementation, but no peer-reviewed, placebo-controlled trial has tested NMN or NR for female pattern hair loss. These claims circulate widely online. They are not supported by published human evidence.

Fertility and Ovarian Aging

Mouse studies from the Sinclair lab showed that NMN improved oocyte quality in aged mice by restoring mitochondrial function, a finding widely cited in fertility supplement marketing. The original mouse study (Bertoldo et al., 2020) used NMN at doses that do not translate directly to human equivalents and assessed oocyte spindle assembly in a model of aged ovaries, not in women undergoing IVF. No human RCT has tested NMN for ovarian reserve, oocyte quality, or live birth rate. This is an active area of research, and any claim beyond "mechanistically interesting, human evidence pending" is premature.

Pregnancy, Lactation, and Contraception: Required Safety Section

NMN and NR are not recommended during pregnancy or breastfeeding.

No human safety data exist for NMN or NR use during pregnancy. Animal studies show NAD+ precursors are required for normal embryonic development; supplemental doses above physiological levels have not been tested in pregnant humans.

The FDA has not assigned a formal pregnancy category to dietary supplements, but the general principle applied to supplements with no human pregnancy data is avoidance. The theoretical concern is not that NMN is toxic but that manipulating NAD+ pathways during organogenesis, when PARP and sirtuin activity regulate gene expression and DNA repair in the developing fetus, carries unknown risk.

Lactation: NMN and NR transfer into breast milk has not been studied. Given the absence of data and the active developmental processes in a nursing infant, avoidance during lactation is the conservative and clinically defensible position.

Contraception: NMN and NR are not teratogenic drugs requiring mandatory contraception, but if you are actively trying to conceive, discuss with your reproductive endocrinologist whether to pause supplementation during the conception window and first trimester pending more data.

One caveat for fertility patients: The mouse oocyte data have led some fertility clinics to offer NMN to women undergoing IVF who have diminished ovarian reserve. If your clinic recommends this, ask for the specific human trial evidence supporting that recommendation. As of mid-2025, it does not exist.

Dosing, Formulations, and What the Trials Actually Used

No consensus clinical dosing guideline exists for NMN or NR because neither is an approved drug. The doses used in published human trials range from 250 mg/day to 1,200 mg/day for NMN and 250 mg/day to 1,000 mg/day for NR.

Formulation Differences

• Oral capsule NMN: The formulation used in the Yoshino trial. Absorbed in the small intestine; peak plasma NMN within 2 to 3 hours.
• Sublingual NMN: Marketed for faster absorption; no head-to-head pharmacokinetic trial against oral capsule in women has been published.
• NR chloride: The most studied NR salt; data from Martens et al. 2022 show dose-dependent blood NAD+ at 1,000 mg/day.
• Liposomal NMN: Claimed to improve bioavailability; no peer-reviewed PK data in humans as of 2025.

Sex-Specific Pharmacokinetics

Women generally have lower body water volume and different hepatic enzyme expression compared to men of similar weight, which affects the distribution and clearance of water-soluble compounds. No NMN or NR pharmacokinetic study has been powered to detect sex differences. This is a genuine gap. Dosing recommendations derived from mixed-sex studies may not be optimal for women.

Timing and Cycle Considerations

Mitochondrial biogenesis and NAD+ demand fluctuate across the menstrual cycle, with higher oxidative phosphorylation activity in the luteal phase. Whether NMN dosing should be adjusted by cycle phase is purely theoretical at this point. No trial has tested this.

Who This Is Right For and Who Should Wait

Most Likely to Benefit (Based on Available Evidence)

• Postmenopausal women with prediabetes or early insulin resistance who have already optimized diet, exercise, and sleep, and whose clinician agrees to monitor response.
• Women with established metabolic syndrome who are not yet candidates for pharmacologic intervention and want an adjunct with a plausible mechanism.

Evidence Is Too Thin to Recommend For

• Women with PCOS seeking to improve insulin sensitivity. Metformin has decades of RCT data in this population. ACOG recommends metformin as first-line pharmacologic therapy for PCOS-related insulin resistance, not experimental supplements.
• Women with diminished ovarian reserve hoping to improve egg quality. The mouse data are intriguing; the human data are absent.
• Women with perimenopausal symptoms expecting hormonal relief. NMN does not affect estrogen, progesterone, or LH levels in any published trial.

Clear Contraindications

• Pregnancy (no safety data; theoretical developmental risk).
• Breastfeeding (no lactation transfer data).
• Active cancer treatment (NAD+ supports DNA repair; theoretical concern about supporting tumor survival, though no clinical trial has addressed this in humans and the risk is speculative).

What Good Evidence Would Actually Look Like

The field needs three things to move from "plausible mechanism" to "clinical recommendation" for women:

1. A powered, sex-stratified RCT in at least 200 postmenopausal women with a metabolic primary endpoint and at least 6 months of follow-up.
2. A prospective cohort or registry linking NMN/NR use to hard outcomes: T2D incidence, cardiovascular events, or fracture. Given supplement status, this would require proactive registry design similar to the Women's Health Initiative methodology.
3. Pharmacokinetic studies stratified by menopausal status, body composition, and hormonal contraceptive use, since combined oral contraceptives alter hepatic NAD+ metabolism through effects on B-vitamin cofactors.

Until that data exists, NMN and NR sit in the category of supplements with a genuine mechanistic rationale, one good small trial in the right female population, and insufficient evidence to recommend at a population level.

The Menopause Society's 2023 position statement on non-hormonal therapies does not include NMN or NR because the evidence does not yet meet its threshold for a formal recommendation. That is where the evidence stands.